live influenza vaccine (freeze-dried) / Changchun BCHT Biotechnology - LARVOL DELTA

Live attenuated influenza vaccine with low proportions of defective interfering particles elicits robust immunogenicity and cross-protection. (PubMed, Nat Commun) - "Compared to the commercially sourced high DIPs LAIV, the low DIPs LAIV elicits enhanced mucosal and humoral immune responses, facilitates cross-neutralization in mice, and provides complete protection against lethal challenges with H3N2, H1N1 or H1N1pdm09 strains. This study offers insights into optimizing commercial LAIVs and replicative RNA virus-based vaccines by controlling DIPs."

Journal • Infectious Disease • Influenza • Respiratory Diseases

Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination (clinicaltrials.gov) - P3 | N=6680 | Not yet recruiting | Sponsor: Changchun BCHT Biotechnology Co.

New P3 trial • Infectious Disease • Influenza • Respiratory Diseases

Effectiveness and safety of a novel intranasal influenza vaccine in Chinese children: A phase IV multi-Center, randomized, double-blind, placebo-controlled clinical trial. (PubMed, Vaccine) - "Ganwu® vaccine provided moderate protection against laboratory-confirmed influenza among children with good safety profile."

Clinical • Journal • P4 data • Infectious Disease • Influenza • Pediatrics • Respiratory Diseases

Immunogenicity and safety of live attenuated influenza vaccine in children aged 3-17 years in China. (PubMed, Vaccine) - "(3) Although there was no significant difference in frequencies of all solicited or unsolicited AEs, nasal congestion, headache, and muscle pain were statistically significantly more frequent in vaccine recipients as compared to placebo Seroconversions and geometric mean fold increases in HI antibody titers against all strains were significantly higher in the vaccine group than in the placebo group. (4) The LAIV is safe and immunogenic in Chinese children and adolescents."

Clinical • Journal • Infectious Disease • Influenza • Musculoskeletal Pain • Pain • Pediatrics • Respiratory Diseases

Post-marketing Study of Lyophilized Nasal Spray Live Attenuated Influenza Vaccine (clinicaltrials.gov) - P4 | N=6080 | Recruiting | Sponsor: Changchun BCHT Biotechnology Co.

New P4 trial • Infectious Disease • Influenza • Respiratory Diseases

Safety and Viral Shedding of Live Attenuated Influenza Vaccine (LAIV) in Chinese Healthy Juveniles and Adults: A Phase Ⅰ Randomized, Double-Blind, Placebo-Controlled Study. (PubMed, Vaccines (Basel)) - "Pathogenicity of shed vaccine virus to surrounding people was not observed. Thus, Phase Ⅱ study can be carried out as scheduled."

Clinical • Journal • Infectious Disease • Influenza • Respiratory Diseases